ABCL - CIK 0001703057
AbCellera Biologics Inc. (ABCL) reported net income of -$146.41M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$146.41M | +10.1% |
| FY 2024 | -$162.86M | -11.2% |
| FY 2023 | -$146.40M | -192.4% |
| FY 2022 | $158.52M | +3.3% |
| FY 2021 | $153.46M | +29.1% |
| FY 2020 | $118.92M | +5478.5% |
| FY 2019 | -$2.21M | - |
AbCellera Biologics Inc. (ABCL) reported net income of -$146.41M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, AbCellera Biologics Inc.'s net income declined from -$2.21M to -$146.41M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.